MindMed Reports First Quarter 2023 Financial Results and Business Highlights
– Key MM-120 readouts in GAD (Phase 2b) and ADHD (Phase 2a) expected by end of 2023 – – MM-402 pre-clinical data in ASD model to be presented at ASCP 2023 Annual Meeting – – Strengthened leadership team with appointment of Mark R. Sullivan as C